Quince Therapeutics (NASDAQ:QNCX) Upgraded to Strong-Buy at Lifesci Capital

Quince Therapeutics (NASDAQ:QNCX) was upgraded by equities researchers at Lifesci Capital to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other research firms have also recently issued reports on QNCX. Weiss Ratings cut Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Zacks Research upgraded shares of Quince Therapeutics to a “hold” rating in a research report on Wednesday, June 24th. Cantor Fitzgerald started coverage on Quince Therapeutics in a research report on Tuesday, June 23rd. They set an “overweight” rating and a $80.00 price objective on the stock. Wall Street Zen upgraded Quince Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Finally, Leerink Partners began coverage on Quince Therapeutics in a research report on Wednesday, June 24th. They issued an “outperform” rating and a $80.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $690.00.

Quince Therapeutics Stock Down 2.4%

Shares of QNCX opened at $0.92 on Monday. The stock has a market capitalization of $15.01 million, a P/E ratio of -0.09 and a beta of 1.40. Quince Therapeutics has a twelve month low of $0.79 and a twelve month high of $45.50. The firm has a fifty day simple moving average of $1.11 and a two-hundred day simple moving average of $9.47.

Quince Therapeutics (NASDAQ:QNCX) last posted its earnings results on Monday, May 11th. The company reported ($11.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($26.00) by $14.20. Sell-side analysts expect that Quince Therapeutics will post -0.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of QNCX. XTX Topco Ltd purchased a new position in Quince Therapeutics in the 2nd quarter worth approximately $37,000. Intellectus Partners LLC bought a new stake in Quince Therapeutics in the 4th quarter worth about $179,000. Bridgeway Capital Management LLC raised its position in Quince Therapeutics by 20.9% in the 2nd quarter. Bridgeway Capital Management LLC now owns 128,617 shares of the company’s stock worth $212,000 after buying an additional 22,200 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Quince Therapeutics during the 4th quarter valued at about $213,000. Finally, Quadrature Capital Ltd bought a new position in Quince Therapeutics during the 4th quarter valued at about $268,000. 30.75% of the stock is owned by hedge funds and other institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.